Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse
Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Prehospital or Early Inhospital (Emergency Department) Thrombolysis With Metalyse ®
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- Male and female patient with suspected myocardial infarction, e.g. during transportation to the hospital by ambulance. No patient younger than 18 years.
- Possibility of obtaining relevant information concerning indication or contraindication of thrombolysis in each patient
- Typical chest pain with a duration of more than 30 minutes
- Definite infarction signs in a 12-lead-ECG with ST-elevation > 0.1 millivolt (mV) in > 2 leads or recent left bundle branch block with typical clinical signs
- Symptom onset <= 6 hours
Exclusion criteria:
- Patients older than 75 years (exception: patients appear much younger)
- Low body weight
- No persons under 18
- contraindications according to summary of product characteristics (SPC) for Metalyse
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Metalyse
Metalyse weight-adjusted
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete ST-segment resolution
Time Frame: up to 30 days
|
up to 30 days
|
|
|
Pain relief
Time Frame: 90 min, 120 min, up to 30 days after treatment initiation
|
yes/no question
|
90 min, 120 min, up to 30 days after treatment initiation
|
|
Change in creatine kinase (CK)
Time Frame: up to 24 hours
|
up to 24 hours
|
|
|
Change in creatine kinase-MB (CK-MB)
Time Frame: up to 24 hours
|
up to 24 hours
|
|
|
Change in troponin
Time Frame: up to 24 hours
|
up to 24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1123.16
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.